白介素-12治疗支气管哮喘的研究进展

支气管哮喘（哮喘）是一种气道慢性炎症性疾病，具有较高的发病率和病死率。作为Thl型细胞因子，IL-12能促进Th0向Thl分化，抑制Th2型炎症反应。大量的动物实验已经证实，IL-12无论单独应用还是作为免疫佐剂，均可逆转哮喘动物体内Th2／Th1失衡和抑制气道变态反应性炎症。同时，IL-12基因治疗在动物实验中也显示了哮喘治疗作用。虽然临床研究显示外源性IL-12治疗哮喘会伴有严重细胞因子毒性作用，但随着用药方式的更新，IL-12可能会成为新一代的抗哮喘药物。

Development of studies on treatment of asthma with IL-12

Bronchial asthma(asthma) which has significant morbidity and leads to high mortality is an inflammatory disease of the airways.As a Th1-type cytokine,IL-12 can stimulate Th0 cell to differentiate into Th1 cell and inhibit Th2-type inflammatory response of asthmatic animal.Numerous animal studies have shown that IL-12,administered alone or as an adjuvant,can reverse the imbalance between Th1 and Th2 cell and inhibit allergic response of airway.Meanwhile,IL-12 gene therapy also indicated the potential role in asthma therapy in many animal studies.Although it is reported in many clinical researches that the serious cytokine toxicity happened when extrinsic IL-12 was administered to patients with asthma,it is possible for IL-12 to be accepted as a new generation of medicine for the treatment of asthma with the innovation of the model of administration.